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Introduction
Organ system development across higher order species requires 
formation of tubular networks. These networks can be found in 
the respiratory system (Affolter and Caussinus, 2008), in the 
vertebrate ureteric system (Costantini, 2006), and most promi-
nently, in the circulatory system, including the blood and 
lymphatic vasculature (Horowitz and Simons, 2008). The archi-
tecture, and therefore function of such systems, is largely deter-
mined  by  one  key  topographical  feature:  branching,  which 
occurs by the sprouting of new tubes from preexisting ones. 
Thus, the molecular mechanisms regulating sprouting are central 
to how a given branching system forms (Horowitz and Simons, 
2008), yet our understanding of this process is limited.
The lymphatic vasculature forms a hierarchical branching 
network that covers the skin and most internal organs of the 
body. The lymphatic system maintains tissue fluid balance by 
recovering fluid from the interstitial space (Alitalo et al., 2005). 
Unlike the circulatory system, the distal-most branches of the 
lymphatic vasculature are blind-ended capillaries that drain into 
larger-collecting lymphatics and return the lymph to the hema-
togenous system via the thoracic duct (Cueni and Detmar, 2006; 
Tammela et al., 2007). Imbalances in circulation of fluid or cells 
can result in lymphedema or disturbed immune responses.
In the mouse, lymph vessel development begins around 
embryonic day 10 (E10) by sprouting from the cardinal veins in 
V
ascular sprouting is a key process-driving devel-
opment of the vascular system. In this study, we 
show that neuropilin-2 (Nrp2), a transmembrane 
receptor for the lymphangiogenic vascular endothelial 
growth factor C (VEGF-C), plays an important role in lym-
phatic vessel sprouting. Blocking VEGF-C binding to Nrp2 
using antibodies specifically inhibits sprouting of develop-
ing lymphatic endothelial tip cells in vivo. In vitro analyses 
show that Nrp2 modulates lymphatic endothelial tip cell 
extension and prevents tip cell stalling and retraction dur-
ing vascular sprout formation. Genetic deletion of Nrp2 
reproduces the sprouting defects seen after antibody treat-
ment. To investigate whether this defect depends on Nrp2 
interaction with VEGF receptor 2 (VEGFR2) and/or 3, we 
intercrossed heterozygous mice lacking one allele of these 
receptors. Double-heterozygous nrp2vegfr2 mice develop 
normally without detectable lymphatic sprouting defects. 
In contrast, double-heterozygote nrp2vegfr3 mice show a 
reduction  of  lymphatic  vessel  sprouting  and  decreased 
lymph vessel branching in adult organs. Thus, interaction 
between Nrp2 and VEGFR3 mediates proper lymphatic 
vessel sprouting in response to VEGF-C.
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Results
Tail dermal lymphatics as a model system 
for studying developmental 
lymphangiogenesis
The superficial dermal lymphatic network of the adult mouse 
tail  consists  of  a  hexagonal  lattice  of  lymphatic  capillaries 
(Hagendoorn et al., 2004). At each junction in this matrix, there 
is a multiringed lymphatic vessel complex (hereafter referred to 
as lymphatic ring complexes [LRCs]) that connects the superficial 
network to collecting ducts. Initially, we performed a develop-
mental analysis of lymphatic network formation. As the network 
largely forms after birth by sprouting from the major lateral 
lymphatic vessels that lie in the deeper dermis and the mature 
hexagonal pattern is established by postnatal day 10 (P10), we 
restricted our analysis to this early postnatal time frame (Fig. 1). 
We found that grossly, the lymphatic vessels have an irregular, 
discontinuous pattern at early time points (P2; Fig. 1 A) with 
only few LRCs comprised of only single-ringed vessels (Fig. 1 E). 
Multiple lymphatic endothelial cells (LECs) with numerous 
filopodial extensions, which are morphologically similar to the 
tip cells that have been described at the ends of growing blood 
vessels (Gerhardt et al., 2003, 2004), protrude from the LRC 
(Fig. 1 I). By P4, the network takes on a regular rhomboid pat-
tern (Fig. 1 B). At this point, the LRC is more prevalent and is 
comprised of 2–3 ringed structures (Fig. 1 F) with numerous tip 
cells (Fig. 1 J). These tip cells are occasionally seen contacting 
each other or stalk cells to form adjacent rings. By P6, the over-
all pattern becomes more hexagonal (Fig. 1 C), driven in part by 
the expansion of the LRCs, which now have 4–5 rings (Fig. 1 G). 
Tip cells are still extended from the rings but are rarer in com-
parison with P4 (Fig. 1 K). By P8, the regular hexagonal pattern 
that is seen in the adult tail is established (Fig. 1 D). The LRCs 
are composed of four to six rings (Fig. 1 H) and now extend 
above and below the plane of the network, appearing more 3D.   
Tip cells are generally not seen protruding from the rings   
(Fig. 1 L). Thus, it appears that the development of the LRC is 
a key to the formation of the regular hexagonal pattern and   
acquires increasing complexity by a sprouting process over the 
first postnatal week of life.
Inhibition of Nrp2 results in abnormal tail 
dermal lymphangiogenesis
To understand the role of Nrp2 in lymphatic development, we 
studied the consequences of Nrp2 inhibition in this tail dermal 
lymphangiogenesis model (Fig. 1). We inhibited Nrp2 using a 
function-blocking  anti-Nrp2  antibody  that  selectively  blocks 
the binding of VEGF family ligands to Nrp2 (anti-Nrp2
B; Caunt 
et al., 2008). This antibody also blocks VEGF-C function in   
vitro in VEGFR2 and VEGFR3 activation assays and in vivo 
(Caunt  et  al.,  2008). Anti-Nrp2
B  treatment  has  a  significant   
impact on the development of rings in the dermal lymphatic 
network. As noted, the control anti-ragweed–treated LRCs were 
comprised of four to six rings (Fig. 1 N) with a complex 3D   
topography.  In  contrast,  the  anti-Nrp2
B–treated  LRCs  were   
simpler, generally comprised of one to two rings (Fig. 1 R). 
Quantification of the number of branch points in control and 
the jugular and perimesonephric area to form lymph sacs. From 
these lymph sacs, vessels subsequently grow by proliferation 
and centrifugal sprouting toward the skin and internal organs 
(Maby-El Hajjami and Petrova, 2008; Oliver and Srinivasan, 
2008). After the initial differentiation and budding of lymphatic 
vessels, which is regulated by Prox-1 and Sox-18 (Wigle et al., 
2002; François et al., 2008), their subsequent migration, growth, 
and survival are mainly controlled by VEGF-C (Karpanen and 
Alitalo, 2008; Maby-El Hajjami and Petrova, 2008). Homo-
zygous vegf-c–null mice show Prox1-positive cells in their car-
dinal veins, but these cells fail to migrate and form the primary 
lymph sacs, resulting in the complete absence of lymphatic vas-
culature in mouse embryos (Karkkainen et al., 2004). Over-
expression of VEGF-C in transgenic mouse models or using 
viral delivery systems is a potent inducer of lymphatic endo-
thelial survival, growth, migration, and proliferation (Jeltsch   
et al., 1997; Wirzenius et al., 2007).
VEGF-C binds to Flt-4/VEGF receptor 3 (VEGFR3), a 
receptor tyrosine kinase that is expressed at early stages of 
lymphatic vessel formation (Joukov et al., 1996). VEGFR3 
appears to be the main signal-transducing receptor mediating 
VEGF-C actions during lymphatic vessel growth (Veikkola 
et al., 2001). However, in addition to VEGFR3, VEGF-C also 
binds additional receptors including VEGFR2 (Skobe et al., 
1999)  and  coreceptors  including  the  neuropilin-2  (Nrp2)   
receptor  (Karkkainen  et  al.,  2001)  expressed  on  veins  and 
lymphatic vessels. Nrp2 was initially identified as a class 3 
semaphorin receptor and mediator of axon guidance (Chen   
et al., 1997; Giger et al., 1998). Homozygous nrp2 mutants show 
a reduction of small lymphatic vessels and lymphatic capillar-
ies, indicating that Nrp2 is not required for lymphatic devel-
opment  but  modulates  it  (Yuan  et  al.,  2002).  Moreover, 
inhibition of Nrp2 using a monoclonal antibody that selec-
tively blocks VEGF-C binding to Nrp2 resulted in a reduction 
of tumor lymphangiogenesis and metastasis, which is a result 
with significant clinical implications (Caunt et al., 2008). How-
ever, these experiments did not address the mechanism by 
which Nrp2 mediates lymphangiogenesis in developmental or 
pathological contexts.
In this study, we show that in vivo modulation of Nrp2 
using blocking antibodies or genetic reduction of Nrp2 levels 
results in selective disruption of lymphatic sprout formation 
without  affecting  other  aspects  of  lymphatic  development. 
The inhibition of sprout formation appears to be a result of 
altered behavior of tip cells at the leading ends of lymphatic 
vessel sprouts. Finally, we show that Nrp2 genetically inter-
acts with VEGFR3 and not VEGFR2, indicating that Nrp2 
partners with VEGFR3 to mediate lymphatic vessel sprout-
ing. Thus, like in the nervous system, where Nrp2 mainly   
regulates axon guidance, its function in the lymphatic vascu-
lature appears to affect a particular step of formation of the 
lymphatic  tree.  However,  although  the  guidance  functions 
Nrp2 exerts in response to semaphorins in the nervous system 
are mainly repulsive and mediate growth cone collapse (Chen 
et  al.,  2000),  they  appear  to  be  attractive  in  the  vascular   
system, mediating tip cell extension and guided vessel sprout-
ing in response to VEGF-C.117 Nrp-2 mediates lymphatic sprouting • Xu et al.
of sprouting lymphangiogenesis in the small intestine and con-
firmed that the intestinal lymphatic network provides another 
ideal system for studying lymphatic sprouting, with sprout initi-
ation occurring between P0 and P2 (Fig. 2, A–D). Next, we   
injected anti-Nrp2
B starting at P1 during sprout initiation (Fig. 2 E) 
to study effects on sprout formation. Nrp2 inhibition resulted in 
a reduction of the number of villi with sprouts compared with 
control-treated animals (Fig. 2, G–J). The percent of villi with 
lacteals dropped significantly from 52% in control-treated ani-
mals to 28% in anti-Nrp2
B–treated animals (P = 0.004; Fig. 2 I). 
Interestingly, the mean length of a lacteal was not affected by 
anti-Nrp2
B treatment (30.7 in control animals vs. 31.4 in anti-
Nrp2
B–treated animals; P = 0.54; Fig. 2 J), suggesting that once 
anti-Nrp2
B–treated animals showed a significant reduction from 
7.4 to 4.6, respectively (P < 0.0001; Fig. 1, P, T, and U). As a re-
sult of the less-complex, smaller rings, the network retained the 
rhombus pattern rather than maturing to the hexagonal pattern 
(Fig. 1, M and Q).
Nrp2 inhibition results in reduced 
lymphatic sprout formation
To examine whether Nrp2 inhibition affected the sprouting pro-
cess, we evaluated the effects of anti-Nrp2
B on the development 
of another lymphatic network with stereotypic pattern and 
sprouting behavior, the intestinal lymphatic network (Fig. 2;   
Kalima, 1971). Again, we performed a developmental analysis 
Figure 1.  Nrp2 inhibition results in abnormal tail dermal lymphangiogenesis. (A–L) Developmental time course of tail dermal lymphangiogenesis by 
whole-mount LYVE-1 immunohistochemistry at P2, 4, 6, and 8. The tails are imaged to show the overall lymphatic network pattern (A–D), to demonstrate 
representative ring complexes (E–H), and to demonstrate tip cells extending from the complexes (I–L). (M–U) Treatment with anti-Nrp2
B results in alteration 
of lymphangiogenesis. The lymphatics in anti-Nrp2
B–treated tails at P8 after treatment at P1, 3, and 5. 3D projections of the confocal images in control 
(O) and anti-Nrp2
B–treated ring complexes (S) in N and R, respectively. The bottom projection is rotated 45° to provide depth perspective. (P and T) Rep-
resentative examples of junctions with dots to denote tallied branch points in control (P) and anti-Nrp2
B (T)–treated tails. (U) Quantification of branch points 
in ring complexes of control and anti-Nrp2
B–treated tails (n = 10 junctions/animal for six animals per condition; *, P < 0.0001). Error bars indicate SEM.   
Bars: (A–D, M, and Q) 250 µm; (E–H) 60 µm; (I–L) 25 µm; (N–R) 75 µm.JCB • VOLUME 188 • NUMBER 1 • 2010   118
Figure 2.  Nrp2 inhibition reduces lymphatic sprouting in developing intestinal and epicardial lymphatics. (A–D) Developmental time course of intestinal 
lymphangiogenesis by LYVE-1 immunohistochemistry. (A) At P0, lymphatics are restricted to the submucosa (arrows). (B) By P2, lymphatic branches have 
extended into a portion of some villi, and newly formed sprouts (arrows) can be seen to form on the submucosal lymphatic vessel adjacent to other villi.   
Tip cells with filopodia (inset) are present on the growing lacteals. (C and D) By P4 (C), most villi have a developing lacteal, which extends to the villus tip by   
P8 (D). Tip cells (inset) can still be observed at the ends of the vessels. (E) Scheme of the time course of lymphatic sprouting into intestinal villi and representa-
tion of experiments shown in G, I, and J. Anti-Nrp2
B was injected i.p. at P1, 3, and 5 (red dots), animals were sacrificed at P8, and tissues were analyzed.   
(F) Schematic representation of experiment shown in H, K, and L. Anti-Nrp2
B was injected i.p. at P3, 5, and 7 (red dots), animals were sacrificed at P10, 
and tissues were analyzed. (G–J) Analysis of intestines from the experiment depicted in E. (G and H) Control-treated intestines (G) have a normal-appearing 
lymphatic pattern in contrast to anti-Nrp2
B–treated intestines (H) in which a larger portion of villi lack lacteals. (I and J) Quantification of the percent of villi 
that have lacteals and villi length. (I–L) 50 villi per animal for six animals per treatment condition were analyzed. (M–P) Control (M and N) and anti-Nrp2
B 
(O and P)–treated hearts showing reduced branching and increased vessel thickness in portions of the anti-Nrp2
B–treated hearts. Error bars indicate SEM. 
Bars: (A–D) 250 µm; (G and H) 125 µm; (M–P) 400 µm.119 Nrp-2 mediates lymphatic sprouting • Xu et al.
Anti-Nrp2
B treatment in vitro  
reduces sprout formation and alters  
tip cell behavior
To directly evaluate the cellular basis for why Nrp2 inhibition 
affects sprout development, we tested the effects of anti-Nrp2
B 
on LEC sprouting using an in vitro sprouting assay. Over the 
course of 14 d, the LECs form sprouts that radially extend from 
the  bead  and  often  display  lumen  formation  and  branching, 
which is highly reminiscent of lymphatic vessel sprouting in 
vivo. In the presence of VEGF-C, the LECs proliferate and form 
robust sprouts that extend from the bead (Fig. 4, A and B). 
Treatment with anti-Nrp2
B reduced the number of sprouts   
(Fig. 4, C and D). Stimulation by VEGF-C resulted in an increase 
of sprout number from a mean of 2.4 sprouts per bead to a mean 
of 6.3 sprouts per bead (P < 0.01). Inhibition of Nrp2 by anti-Nrp2
B 
in the presence of VEGF-C resulted in a significant reduction in 
the number of sprouts to 3.7 (P < 0.0001 compared with VEGF-C). 
a sprout was established, inhibition of Nrp2 did not have any   
effect on intestinal lymphatics. This supported the idea that Nrp2 
did not play a role in lymphatic sprout extension. To test this 
possibility, we performed additional experiments in which we 
initiated anti-Nrp2
B treatment at P3, after sprout initiation, and 
during extension of the developing lacteals (Fig. 2 F). As pre-
dicted, inhibition of Nrp2 at this point did not have significant 
impact on lymphangiogenesis (Fig. 2, K and L). We also tested 
the effect of anti-Nrp2
B treatment on mature, established lym-
phatic vessels in many organs including the intestines, skin, and 
pancreas. Extended treatment with high dose (100 mg/kg) anti-
Nrp2
B for 25 wk did not alter lymphatic structure (Fig. S1).
Additionally, we characterized the pattern of lymphatic 
development in the heart, which has a highly branched surface 
epicardial lymphatic network (Fig. 2, M–P) that develops from 
P0 onward (Yuan et al., 2002). We noted that although at P8 
control  hearts  have  a  highly  branched  lymphatic  network   
(Fig. 2, M and N), treatment with anti-Nrp2
B resulted in the 
simplification of the network with a reduction in the number of 
branches (Fig. 2, O and P). In addition, the anti-Nrp2
B–treated 
lymphatic vessels were strikingly enlarged compared with the 
control-treated vessels (Fig. 2, N and P), suggesting that lym-
phatic  cell  expansion  was  ongoing,  but  rather  than  forming 
sprouts, the vessels were instead increasing in size.
Tip cell abnormalities develop upon 
treatment with anti-Nrp2
B
Our  data  support  the  notion  that  treatment  with  anti-Nrp2
B  
inhibits  sprout  formation  in  three  different  developing  lym-
phatic systems. Furthermore, our observations in the tail dermal 
lymphatics implied that there was a dramatic reduction in the 
number of tip cells that extend from LRC. This raised the possi-
bility that Nrp2 inhibition resulted in a tip cell defect, which   
inhibited sprout formation. Thus, we evaluated whole-mount 
preparations of dorsal trunk skin at P8, which is when dermal 
lymphatics are undergoing a rapid branch expansion and the 
tips of many developing branches have morphologically distinct 
tip cells. In control-treated animals, we noted that the dermal 
lymphatic network was highly branched, and a large proportion 
of branches had a tip cell (5.6 tip cells per high powered field; 
Fig. 3, A, B, and F) with many filopodial extensions. In contrast, 
treatment with anti-Nrp2
B resulted in the loss of these special-
ized cells (2.2 tip cells per high powered field; P < 0.01; Fig. 3, 
C, D, and F) and a reduction in branch number. Although the 
number of tip cells was dramatically reduced, the total vessel 
area appeared unchanged (Fig. 3 E). Furthermore, no morpho-
logical differences were observed with the stalk cells between 
anti-Nrp2
B and control-treated animals, which is consistent with 
Nrp2-mediating tip cell–specific effects.
To further understand the basis of these selective effects 
on tip cells, we evaluated Nrp2 expression on developing   
lymphatics in many of these systems at the time of sprout   
formation. Immunostaining for Nrp2 revealed Nrp2 expression 
in developing lymphatic vessels. Nrp2 was found at higher   
levels in tip cells of new sprouts (Fig. S2) in both dermal   
lymphatics and lacteals. Additionally, Nrp2 was present in   
filopodial extensions emanating from the tip cells.
Figure 3.  Anti-Nrp2
B treatment reduces tip cell number in dermal lym-
phatics. (A–D) Control (A and B) and anti-Nrp2
B (C and D)–treated skin 
showing a reduction in the number of tip cells. The boxed areas in A and 
C are shown at higher magnifications in B and D, respectively. (E) No 
change in lymphatic vessel density was noted between control and anti-
Nrp2
B–treated samples. (F) A significant reduction in the number of tip cells 
per high powered field was noted between control and anti-Nrp2
B–treated 
samples. Error bars indicate SEM. *, P < 0.01. Bars: (A and C) 150 µm; 
(B and D) 70 µm.JCB • VOLUME 188 • NUMBER 1 • 2010   120
To gain further mechanistic insight into how Nrp2 inhi-
bition may affect initial sprout formation, we performed live   
imaging of the bead cultures to observe and analyze tip cell be-
havior in real time in the presence or absence of the anti-Nrp2
B 
antibody. We evaluated the number of sprout initiation events 
and the behavior of sprouts after initiation. We noted that treat-
ment with anti-Nrp2
B did not have any effect on the mean num-
ber of sprout initiation events during the first day of culture 
(Fig. 4 F). This was surprising given our finding of fewer sprouts 
in treated cultures (Fig. 4 D). We also observed that sprouts that 
initiated on control-treated beads generally developed into 
As a positive control for blocking VEGF-C activity, the VEGFR3 
extracellular domain protein (ECD; Mäkinen et al., 2001; Caunt 
et al., 2008) reduced sprouting to 1.7 sprouts per bead, which is 
a level comparable with the no VEGF-C control. Nrp2 inhibi-
tion did not affect mean sprout length (364 pixels in VEGF-C 
treated vs. 314 pixels in anti-Nrp2
B treated; P = 0.09) in contrast 
to VEGFR3 ECD (53 pixels; P < 0.0001; Fig. 4 E). These data 
corroborate our in vivo observations that Nrp2 inhibition results 
in reduced sprouting but not sprout length, likely not affecting 
stalk cells. It also suggested an effect on the initial aspects of 
sprout formation.
Figure 4.  Anti-Nrp2
B treatment in vitro results 
in reduced sprout formation and altered tip cell 
behavior.  (A–C)  Representative  examples  of 
LECs sprouting from coated beads in control 
(A),  VEGF-C  (B)–,  or  anti-Nrp2
B  (C)–treated 
cultures  stained  with  anti–LYVE-1.  (D)  Sprout 
number  is  significantly  reduced  with  anti-
Nrp2
B or VEGFR3 ECD treatment compared 
with VEGF-C treatment alone. (E) Sprout length 
is not reduced with anti-Nrp2
B treatment but is 
reduced by VEGFR3 ECD treatment compared 
with VEGF-C treatment alone (n = 5 beads/
well for 10 wells). (F–I) Quantification of sprout 
initiation events (F), sprout-stalling events (G), 
and sprout extension rates from live imaging 
experiments. Error bars indicate SEM. *, P < 
0.01. Bar, 150 µm.121 Nrp-2 mediates lymphatic sprouting • Xu et al.
Normal lymphatic development in double-
heterozygous nrp2
+/vegfr2
+/ mice
We intercrossed heterozygous nrp2
+/ mice with vegfr2
+/egfp 
mice to test for possible defects in lymphatic vessel develop-
ment in double-heterozygous offspring. Whole-mount analy-
sis of P1 guts showed egfp expression in mesenteric arteries, 
veins, and capillaries covering the gut surface as well as robust 
egfp expression in lymphatic mesenteric vessels (Fig. 5 A). 
Similarly, double labeling of skin isolated from the trunk or 
tail of vegfr2
+/egfp mice with the lymphatic marker LYVE-1 
showed double labeling of lymphatic vessels with both egfp 
and LYVE-1, extending into the tips of sprouting lymphatic 
vessels (Fig. 5, B–B). Arteries, veins, and capillaries expressed 
only egfp. Thus,  consistent  with  the  results  obtained  using   
antibody labeling (Fig. S2), vegfr2 expression was routinely 
detected by this reporter construct in lymphatic vessels includ-
ing sprouting tips.
As the egfp insertion disrupts transcription of the vegfr2 
gene, homozygous vegfr2
egfp/egfp die at early embryonic stages as 
a result of failure of blood vessel formation. However, hetero-
zygous mice are viable and fertile and develop no detectable 
blood vascular or lymphatic malformations. Double-heterozygous 
nrp2
+/vegfr2
+/ mice were born at normal Mendelian ratios (12 
litters, 79 mice, 16 wild type, 25 nrp2
+/, 16 vegfr2
+/, and 22 
nrp2
+/vegfr2
+/). Real-time PCR of hearts isolated from P5 
wild-type and nrp2
+/vegfr2
+/ mice showed that, as expected, 
mRNA levels of flk-1/vegfr2 and nrp2 were decreased by 50% 
in  the  double-heterozygotes  compared  with  wild-type  litter-
mates (Fig. 6 B). In contrast, levels of vegfr3 or podoplanin 
were not significantly different in nrp2
+/vegfr2
+/ compared 
with wild type (Fig. 6 B).
Confocal analysis of whole-mount, double-labeled skins 
stained with LYVE-1 from tail (Fig. 5, D–D) or trunk (Fig. 5, 
E–F) showed no obvious alteration in capillary density or pat-
terning in double- heterozygous compared with vegfr2 single-
heterozygous  skins  (Fig.  5,  compare  B  with  D).  Lymphatic 
vessel patterning and sprouting were also normal (Fig. 5, B and 
D–F). Quantification of lymphatic vessel branch points from 
whole mounts of trunk skins stained with anti-VEGFR3 (not 
depicted) or LYVE-1 showed similar numbers of branch points in 
control (wild-type single heterozygote) and double-heterozygote 
nrp2
+/vegfr2
+/ animals (Fig. 5 C). Collectively, reduction of 
vegfr2 and nrp2 levels to 50% of their normal levels is compati-
ble with normal lymphatic vessel development.
Abnormal lymphatic development in double-
heterozygous nrp2
+/vegfr3
+/ mice
We next used a similar approach to examine the genetic interaction 
between nrp2 and vegfr3 (formally denoted as flt4 but hereafter 
referred to as vegfr3 for clarity). Lymphatic vessel development   
was  evaluated  in  double-heterozygous  nrp2
+/vegfr3
+/  mice.   
X-gal staining of lymphatic vessels from vegfr3
+/lacZ heterozygous 
embryos (Dumont et al., 1998) showed progressive coverage of 
the skin from E13.5 onward (Fig. 6 A, left). Double-heterozygous 
nrp2
+/vegfr3
+/ littermates were of similar size and showed   
no obvious developmental retardation but exhibited reduced   
X-gal–stained vascular coverage in the skin, which is consistent 
larger stable sprouts. In contrast, the sprouts that initiated from 
anti-Nrp2
B–treated beads often stalled (Fig. 4 G) and retracted 
back to the bead (54% stall rate compared with 28% in control 
beads; P = 0.019). Once a sprout had extended to 150 µm in 
length, stalling and sprout elongation rates were not affected by 
inhibition of Nrp2 (Fig. 4, H and I). In these cultures and those 
observed after additional culturing for 48 h, no differences were 
noted in stalk cell behavior between control and anti-Nrp2
B–
treated  cultures. Thus,  Nrp2  inhibition  increased  the  rate  at 
which tip cells, which are initiating lymphatic sprouts, stall and 
retract. This results in a reduction in the number of sprouts   
in vitro and reduced lymphatic sprouting and altered tip cell 
morphology in vivo.
As modulation of cytoskeletal dynamics have been shown 
to be critical for tip cell growth, we evaluated the effects of Nrp2 
inhibition on actin and microtubule cytoskeletal elements in LEC 
in culture. No changes were noted either in control VEGF-C–
stimulated cells or in stimulated cells treated with anti-Nrp2
B 
(Fig. S3). Additionally, no changes in activation of Rac, Rho, or 
Cdc42 were observed (Fig. S3). However, such changes may 
only occur at a subcellular level in actively sprouting tip cells.
LECs express VEGFR2 and VEGFR3  
in vitro and in vivo
Nrp2 is thought to act as a VEGF-C coreceptor and is not known 
to activate any downstream signaling pathways via its intra-
cellular domain. It is believed to work with the VEGFR family 
of  receptor  tyrosine  kinases  to  promote  VEGF-C  signaling 
(Soker  et  al.,  2002;  Favier  et  al.,  2006).  Nrp2  can  promote 
VEGF-C signaling via VEGFR2 and VEGFR3, and inhibition 
of Nrp2 modestly but significantly reduces VEGF-C–mediated 
activation of both receptors (Favier et al., 2006; Kärpänen et al., 
2006; Caunt et al., 2008). Thus, neuropilins serve to augment 
the signaling of VEGF family ligands by VEGFRs.
To determine whether one or both of these receptors could 
interact with Nrp2 during lymphatic development, we investi-
gated which of these VEGFRs are present on LECs. FACS   
analysis demonstrated that cultured LECs express both VEGFR2 
and VEGFR3 (Fig. S2). Immunohistochemical analysis of 
developing lymphatic vessels of the intestine showed that   
as with the cultured LECs, both VEGFR2 and VEGFR3 are 
expressed (Fig. S2), which is in agreement with previous studies 
(Veikkola et al., 2001; Wirzenius et al., 2007). Therefore, we 
performed genetic analysis to determine which of the two   
VEGFRs partners with Nrp2 to functionally drive lymphatic 
sprouting and lymphangiogenesis.
We  intercrossed  heterozygous  mice  lacking  one  allele   
of these receptors. C57/BL6 nrp2vegfr2 or nrp2vegfr3 double-
heterozygous  mice  were  generated  by  interbreeding  nrp2
+/ 
mice (Giger et al., 2000) with mice carrying a knock-in of the 
egfp gene into the flk-1/vegfr2 locus (vegfr2
+/egfp mice) or mice 
carrying  a  b-galactosidase  knock-in  into  the  vegfr3  locus 
(vegfr3
+/lacZ mice; Dumont et al., 1998). Possible lymph vessel 
defects had not been previously analyzed in the present nrp2
/ 
mutants but were highly similar to those described in a different 
nrp2  loss  of  function  mutation  generated  by  a  gene  trap   
approach (Fig. S4; Chen et al., 2000; Yuan et al., 2002).JCB • VOLUME 188 • NUMBER 1 • 2010   122
Mendelian ratios at birth (32 litters, 235 mice, 67 wild type, 59 
nrp2
+/, 69 vegfr3
+/, and 40 nrp2
+/vegfr3
+/), indicating that 
defective lymph vessel sprouting and edema formation in some 
of these embryos might have precluded development to term. 
Real-time PCR analysis of hearts isolated from wild-type and 
nrp2
+/vegfr3
+/ mice at P5 showed that as expected, levels of 
nrp2 and vegfr3 in the nrp2
+/vegfr3
+/ double heterozygotes 
were reduced to 50% of wild-type levels, whereas expression 
levels of pecam-1, flk-1/vegfr-2, prox-1, Lyve-1, and podoplanin 
were not significantly altered (Fig. 6 B). These results confirm 
the histological findings and suggest that lymphatic specification 
occurs normally but that aspects of subsequent development of 
the lymphatic vasculature, notably patterning and sprouting, 
are deficient in the double-heterozygote mice.
Lymphatic sprouting is selectively affected 
in nrp2
+/vegfr3
+/ mice
To further characterize these defects, we used confocal mi-
croscopy analysis of whole-mount–stained skin preparation to 
compare wild-type, single-heterozygote, double-nrp2
+/vegfr3
+/ 
heterozygote, and nrp2
/ lymphatic vessels (Fig. 7). Lymphatic 
vessels were visualized using LYVE-1 or VEGFR3 immuno-
staining with very similar results (Fig. 7 and Fig. S4).
with reduced lymphatic coverage (Fig. 6 A, right). At a higher 
magnification, these X-gal–stained vessels in the skin of the head 
could be seen to sprout and grow toward the dorsal midline in 
vegfr3
+/lacZ heterozygotes (Fig. 6 C), a pattern very similar to that 
observed in wild-type embryos stained with anti-VEGFR3 anti-
body (Fig. S4 A). In contrast, sprouting in the double-heterozygous 
nrp2
+/vegfr3
+/ littermates was strongly reduced and appeared 
similar to the homozygous nrp2 knockout embryos (compare 
Fig. 6 D with Fig. S4 B). Enlarged, sac-like X-gal–stained 
structures were observed beneath the skin in the nrp2
+/vegfr3
+/ 
double heterozygotes (Fig. 6 D). Sectioning of embryos and 
double labeling with CD31 showed no major defect in vessel 
number or patterning between vegfr3 single heterozygotes and 
nrp2
+/vegfr3
+/ double heterozygotes (Fig. 6, E and F). In con-
trast, the number of lymphatic vessel sprouts was strongly re-
duced, and the lymph sacs were strikingly enlarged in the 
nrp2
+/vegfr3
+/ compared with the vegfr3 single-heterozygote 
littermate, suggesting that rather than forming sprouts, lymph 
sacs were growing in size in these embryos (Fig. 6, E and F). 
At this stage, edema formation could be observed by histology 
(Fig. 6 F), but not grossly. In contrast, severe edema formation 
was observed in some nrp2
+/vegfr3
+/ embryos from E15.5 on-
ward (unpublished data), and they were recovered at reduced 
Figure 5.  Normal lymphatic development in double-heterozygous nrp2
+/vegfr2
+/ mice. (A) EGFP staining of mesenteric vessels in a heterozygous   
vegfr2-egfp mouse pup at P0. Note green fluorescence in capillaries covering the surface of the duodenum and in mesenteric arteries, veins, and   
lymphatic vessels. D, duodenum; A, mesenteric arteries; V, veins; L, lymphatic vessels. (B–B) EGFP–LYVE-1 double staining of tail skin at P1. Note Flk-1–EGFP 
expression in a lymphatic vessel sprout (asterisks) and in filopodia-extending tips (arrows). (C) Quantification of lymph vessel branch points. Error bars 
indicate SEM. (D–D) Normal appearance of lymphatic vessel sprouts (asterisks) and filopodia-extending tips (arrows) in P1 tail skin in double-heterozygous 
nrp2
+/vegfr2
+/ mice. (E and F) Lower magnification views of LYVE-1–positive lymphatic vessels in wild-type (E) and nrp2
+/vegfr2
+/ dorsal trunk skin. 
WT, wild type. (F’–F) Flk-1/VEGFR2-EGFP–LYVE-1 double labeling. OV, overlay. Bars: (A) 200 µm; (B–D) 50 µm; (E–F) 200 µm.123 Nrp-2 mediates lymphatic sprouting • Xu et al.
vessels appeared enlarged and poorly branched (Fig. 7, B, C, 
and J; and Fig. S4 N). Quantification of the number of branch 
points using LYVE-1 or VEGFR3 staining showed a 50%   
reduction  in  both  nrp2
+/vegfr3
+/  heterozygote  and  nrp2
/  
mutants compared with wild type (Fig. 7 J). Lymphatic tips 
were rarely seen in the double-heterozygote or nrp2 mutants. 
In the cases where tips were observed, their shape was changed 
Lymph vessels in wild-type mouse skin formed a regular 
array of uniformly sized, branched vessels with some sprout-
ing tips visible in each image (Fig. 7 A and Fig. S4 L). At high   
magnification,  these  tips  were  composed  of  one  or  several   
filopodia-extending cells that were labeled both by LYVE-1 
and VEGFR3 antibodies (Fig. 7 D and Fig. S4 M). In both 
nrp2
+/vegfr3
+/ double-heterozygote and nrp2
/ skins, lymphatic   
Figure 6.  Abnormal lymphatic development in double-heterozygous nrp2
+/vegfr3
+/ mice. (A) X-gal staining (blue) of E13.5 vegfr3
+/ (left) and 
double-heterozygous nrp2
+/vegfr3
+/ (right) littermate embryos. (B) expression levels of lymphatic marker genes as measured by quantitative PCR   
in RNA isolated from hearts of wild-type and double-heterozygote nrp2
+/vegfr2
+/ and nrp2
+/vegfr3
+/ mice. Values significantly different from   
wild-type mice (*, P > 0.05; **, P > 0.001) by Student’s t test are shown. Error bars indicate SEM. (C and D) Higher magnification of heads of   
embryos shown in A. Note numerous lymphatic vessel sprouts in vegfr3
+/ (black arrows) and fewer enlarged lymph vessel sprouts in nrp2
+/vegfr3
+/ 
(red arrows). e, eye; *, ear. (E and F) Transverse section through the neck of E13.5 embryos double stained with X-gal (blue) and CD-31 (brown). 
Note similar development of CD-31–positive arteries, veins, and skin capillaries (arrowheads) in vegfr3
+/ (E) and nrp2
+/vegfr3
+/ (F). Note enlarged 
jugular lymph sacs (asterisks) in nrp2
+/vegfr3
+/ (F) compared with vegfr3
+/ (E). Lymph vessels sprouting from the lymph sac toward the skin are less 
numerous in nrp2
+/vegfr3
+/ compared with vegfr3
+/ (arrows). A, arteries; V, veins; NT, neural tube; Vt, vertebra. Bars: (A) 1.4 mm; (C and D) 0.8 mm; 
(E and F) 150 µm.JCB • VOLUME 188 • NUMBER 1 • 2010   124
Examination of replication of LEC using phospho–histone 
H3/LYVE-1 double staining showed that there was no signifi-
cant difference between the numbers of replicating LECs between 
wild-type and nrp2
+/vegfr3
+/ skins (Fig. 7 K). Replication of 
LEC in nrp2
/ skins was reduced compared with wild-type, 
as previously observed in a different nrp2 mutant allele (Yuan 
et  al.,  2002).  Apoptosis  of  LECs  using  cleaved  caspase-3 
staining was only rarely detected, although some cells in hair 
follicles of the skin were found positive in each genotype. We 
found few positive LECs and therefore find it unlikely that in-
creased apoptosis could be a possible cause for these observa-
tions. CD31 staining showed normally patterned arteries and 
veins in the skin of neonatal nrp2
+/vegfr3
+/ mice, confirm-
ing that the mutation selectively affected lymphatic vessels 
(Fig. 7, G and H).
when compared with wild type: they were composed of nu-
merous cells that failed to extend filopodia (Fig. 7, E and F; 
and  Fig.  S4  O),  reproducing  treatment  with  anti-Nrp2
B. 
Nrp2
/vegfr3
+/ mice showed enhancement of lymph vessel 
enlargement and poor branching (Fig. 7, I and J). Staining of 
wild-type skin sections with alkaline phosphatase (AP)–tagged 
VEGF-C  (VEGF-C–AP)  showed  that  VEGF-C  selectively 
binds to lymphatics. Notably, strong staining was observed for 
tip cells compared with stalk cells (Fig. S5) and is consistent 
with the increased Nrp2 levels found in tip cells (Fig. S2). 
VEGF-C–AP  staining  was  markedly  decreased  in  double-
  heterozygous animals. In comparison, VEGF-A–AP strongly 
bound to blood vessels and only weakly stained lymphatic 
vessels, which is consistent with the immunohistochemistry 
analysis of VEGFRs (Fig. S2).
Figure  7.  Defective  lymphatic  sprouting  in 
nrp2
+/vegfr3
+/ mice. (A–C) Confocal images 
of  LYVE-1–stained  lymph  vasculature  in  the 
dorsal trunk skin at P0. Note enlarged, poorly 
branched vessels in nrp2
+/vegfr3
+/ (B) and 
nrp2
/ (C) compared with wild type (A). Sev-
eral lymphatic tips are present in wild type   
(A, arrows), none are present in nrp2
+/vegfr3
+/   
(B), and one is present in nrp2
/ (C, arrow). 
(D–F)  LYVE-1  (green)/phospho–histone  H3 
(red) DAPI (blue) staining of P0 skin; high mag-
nification views of lymphatic tips are shown. 
Note  filopodial-extending  tips  composed  of 
several  cells  in  wild  type  (D),  whereas  both 
nrp2
+/vegfr3
+/  (E)  and  nrp2
/  (F)  show 
blunt-ended, enlarged tips devoid of filopodial 
extensions. (G and H) CD31 staining shows 
similar patterning of blood vasculature in the 
skin of mice with the indicated genotypes. A, 
arteries; V, veins. (I) Dorsal trunk skin at P0 in a 
nrp2
/vegfr3
+/ mouse. Note enlarged lym-
phatic vessel. (J) Quantification of lymphatic 
vessel branch points in mice of the indicated 
genotypes. (K) Replication of LECs. The num-
ber of phospho–histone H3 (PH3)-positive nuclei 
per millimeter squared of LYVE-1–positive vessels 
was counted. WT, wild type. Error bars indicate 
SEM. **, P < 0.01; ***, P < 0.001. Bars: (A–C) 
200 µm; (D–F) 50 µm; (G–I) 200 µm.125 Nrp-2 mediates lymphatic sprouting • Xu et al.
exhibited reduced lymph vessel branching in these organs (Fig. 
S4, F–K). Examination of functionality of lymph vessels in the 
ear skin using FITC dextran injection showed that although 
they were more poorly branched, lymph vessels in the double 
  heterozygote were capable of transporting dextran (Fig. S4, 
J and K). Cellular junctional proteins were also observed to 
have similar distribution in both wild-type and nrp2
+/vegfr3
+/ 
mice in patterns consistent with those previously described 
(Baluk et al., 2007), suggesting that cell–cell interactions were 
unaffected. This was also observed in cultured cells treated with 
anti-Nrp2
B antibody (Fig. S3).
Finally, smooth muscle coverage of larger collecting lym-
phatic  vessels  was  indistinguishable  between  wild-type  and 
nrp2
+/vegfr3
+/ mice, indicating that lymph vessel maturation 
occurred normally in these animals (unpublished data). Collec-
tively, our analysis shows that nrp2
+/vegfr3
+/ mice exhibit   
selective defects in lymphatic vessel sprouting and recapitulate 
inhibition of Nrp2 by anti-Nrp2
B.
Discussion
The  lymphatic  system  regulates  fluid  homeostasis,  immune 
system function, and is involved in initiation of tumor cell dis-
semination or metastasis for many solid tumor types. As such, 
elucidating the molecular mediators of lymphatic development 
is of significant importance. Our recent studies have impli-
cated Nrp2 as a modulator of lymphangiogenesis both in the 
context of development and tumor biology (Yuan et al., 2002; 
Caunt et al., 2008). The results presented in this study show 
that in vivo modulation of Nrp2, either by genetic or pharma-
cologic means, results in disruption of lymphatic sprout for-
mation by altering tip cell behavior. We further show that Nrp2 
genetically interacts with VEGFR3 and not VEGFR2, indicat-
ing that Nrp2 partners with VEGFR3 to modulate lymphatic 
vessel sprouting.
Nrp2 is necessary for selective aspects of 
VEGF-C–mediated lymphangiogenesis
VEGF-C has been implicated in many aspects of lymphangio-
genesis, including LEC survival, proliferation and migration, 
vessel growth, and the formation of vessels/vascular structures 
by signaling through VEGFR3 (Alitalo et al., 2005). However, 
proteolytically processed VEGF-C can also bind to VEGFR2 
(Joukov et al., 1997), which is also expressed on lymph vessels 
and has been implicated in lymphangiogenesis (Hong et al., 
2004; Goldman et al., 2007). Additionally, Nrp2 has been shown 
to be a VEGF-C coreceptor without any inherent signaling role 
(Karkkainen et al., 2001; Favier et al., 2006; Kärpänen et al., 
2006). Primarily, Nrp2 has been proposed to function to augment 
signaling of VEGF-C via the receptor tyrosine kinases VEGFR2 
and VEGFR3 (Favier et al., 2006). Indeed, inhibition of Nrp2 
function in vitro results in a reduction in VEGFR2 and VEGFR3 
phosphorylation by VEGF-C (Caunt et al., 2008). Thus, one 
might predict that inhibition of Nrp2 should result in modest   
reduction  of  all  of  the VEGF-C–mediated  lymphangiogenic   
activities attributed to VEGF-C. In fact, we show that Nrp2 
plays a role in only a specific aspect of lymphangiogenesis: 
Tip cell abnormalities in nrp2
+/vegfr3
+/ 
mice are similar to those obtained after 
anti-Nrp2
B treatment
As lymphatic tip cell defects in the neonatal skin of nrp2
+/-
vegfr3
+/ mice were highly reminiscent of the defects seen in 
the skin after anti-Nrp2
B treatment (Fig. 3), we next compared 
lymphatic development in these mice with the effects of anti-
Nrp2
B administration in previously described model systems.
Tail  dermal  lymphatics  were  missing  in  the  nrp2
+/-
vegfr3
+/ double heterozygotes until at least P6 (Fig. S5). In 
contrast, the central collecting lymphatics of the tail were al-
ready present at P1 and exhibited the characteristic enlargement 
and lack of sprouting observed in the trunk skin (unpublished 
data). Sectioning of the tails and staining with VEGF-C–AP 
showed  that  VEGF-C  selectively  decorated  lymphatics,  in   
particular sprouting lymphatics (Fig. S5 E). For comparison, 
VEGF-A–AP  strongly  bound  to  microvessels  (Fig.  S5  F).   
Although  wild-type  tails  showed  two  concentric  layers  of   
lymphatic  vessels,  an  inner  layer  comprising  the  collecting   
lymphatics and an outer dermal layer (Fig. 1 and Fig. S5 E), 
only the inner collecting layer developed in nrp2
+/vegfr3
+/ 
double-heterozygotes and nrp2
/ mutants (Fig. S5, G and I). 
Lymphatics in this layer still bound VEGF-C, as expected from 
the presence of VEGFR3 on these vessels in both mutants, but 
they enlarged rather than formed sprouts in the mutant back-
ground and represent an earlier phenotype compared with anti-
body treatment. Thus, lack of Nrp2 or reduction of Nrp2 and 
VEGFR3 levels on tail lymphatics leads to selective lack of 
lymphatic vessel sprouting.
We next examined the small intestine and hearts of the 
nrp2
+/vegfr3
+/ and nrp2
/ mice. In those tissues, sprouting 
and coverage of the lymphatics only begins at birth, and the ef-
fects of antibody treatment could thus be expected to mirror 
mutation  of  nrp2  or  genetic  reduction  of  nrp2  and  vegfr3  
expression levels. In the heart, both nrp2
/ mice (Fig. S4)   
and  nrp2
+/vegfr3
+/  double  heterozygotes  showed  reduced 
lymphatic vessel sprouting and lymphatic vessel enlargement 
compared with vegfr3
+/LacZ (Fig. 8, A and B), a phenotype   
highly similar to the one observed after anti-Nrp2
B treatment 
(Fig. 2, O and P).
In the small intestine, both wild-type and nrp2
+/vegfr3
+/ 
mice at P4 had a submucosal lymphatic plexus established (Fig. 
8, C–E). However, nrp2
+/vegfr3
+/ mice showed a striking re-
duction of the number of villi-containing sprouting lymphatics 
when compared with wild-type controls (Fig. 8, C–F). Interest-
ingly, in a few sections of the double-heterozygote mice, some 
of the villi were already invaded by lymphatics (Fig. 8 E), and 
these appeared similar in length when compared with the wild-
type villi (Fig. 8 C), which is consistent with the finding that 
anti-Nrp2
B treatment affected the initial sprouting event but not 
sprout elongation. At P8, most of the villi in nrp2
+/vegfr3
+/ had 
mature lacteals that appeared indistinguishable from the wild-
type littermates (unpublished data), confirming that inhibition 
of Nrp2-VEGFR3 function selectively affected the initial sprout 
formation in this tissue but not subsequent growth of the sprouts.
Comparison of lymphatic vessel patterning in adult vegfr3
+/ 
and nrp2
+/vegfr3
+/ mice showed that double-heterozygote mice JCB • VOLUME 188 • NUMBER 1 • 2010   126
previously described differential activities of VEGF family 
ligands that selectively activate either VEGFR2 or VEGFR3. 
Ligands that selectively activate VEGFR3 but not VEGFR2 
induce lymphatic sprouting, whereas ligands that selectively 
activate VEGFR2 but not VEGFR3 lead only to enlargement of 
lymphatic capillaries but fail to induce sprouting (Veikkola et al., 
2001; Wirzenius et al., 2007).
The molecular basis for Nrp2’s selective action in sprout-
ing lymphatic tips is unclear. It is possible that Nrp2 provides 
functionality  to  specifically  modulate  tip  cell  extension,   
potentially by conveying additional molecular mediators to 
the VEGFR complex. Consistent with this, Nrp2 intracellular 
sprout formation. Furthermore, we assign a more specific role 
to Nrp2, preventing tip cell stalling and retraction, thereby mod-
ulating lymphatic endothelial tip cell stability. In contrast, stalk 
cell behavior largely appears unaffected by Nrp2 inhibition. 
These findings are consistent with the observation that Nrp2 
protein is enriched in cells at the leading tip of growing lym-
phatic sprouts (Caunt et al., 2008) in tip cell filopodia and that 
VEGF-C–AP more strongly stains lymphatic tip cells (Fig. S5). 
A  selective  role  in  modulating  some  but  not  all  aspects  of 
VEGF-C biology has been previously noted (Caunt et al., 2008), 
but this is the first study to associate a cellular basis for this   
observation.  This  also  provides  a  biological  basis  for  the   
Figure  8.  Tip cell abnormalities in nrp2
+/-
vegfr3
+/ mice are similar to those obtained 
after  anti-Nrp2
B  treatment.  (A  and  B)  X-gal 
staining  of  P5  hearts  from  mice  of  the  indi-
cated genotypes. Note regular branching of 
lymphatics in the vegfr3
+/ heart (A) but en-
larged,  poorly  branched  vessels  devoid  of 
sprouting tips in the double-heterozygote heart 
(B). (C–F) Lymphatic sprouting defects in the 
small intestine at P4. LYVE-1–stained sections 
show presence of lymphatics in almost all villi 
of wild-type mice (C) but virtually no sprouts 
in  most  sections  of  the  double-heterozygous 
mice (D). Only some sections show a portion 
of the villi-containing lymphatics (E), which are 
of normal length compared with wild type (C). 
(F)  Quantification  of  the  percentage  of  villi-
containing lymphatics. *, P < 0.01. Error bars 
indicate SEM. Bars: (A and B) 210 µm; (C–E) 
200 µm.127 Nrp-2 mediates lymphatic sprouting • Xu et al.
anti-Nrp2
B antibody. This suggests that Nrp2’s role as a VEGF-C 
coreceptor is central to mediating lymphatic sprouting and that 
its role as a coreceptor for other ligands, including those that 
have been implicated in lymphangiogenesis such as hepatocyte 
growth factor (Jiang et al., 2005; Kajiya et al., 2005; Cao et al., 
2006; Sulpice et al., 2008), is not significant for developmental 
lymphatic biology.
Tip cell extension in the lymphatic system
The biological phenomenon of sprouting in general, and more 
specifically tip cell extension, is incompletely understood. It 
is likely to involve the interplay between negative and positive 
regulators as in other systems that rely on branching morpho-
genesis  (Horowitz  and  Simons,  2008). Within  the  vascular 
system, lymphatic vessels exhibit several unique characteris-
tics, including the fact that some of the tips remain blind ended 
throughout life and develop functional specializations that 
allow fluid entry (Baluk et al., 2007). Currently, much of our 
limited understanding of vessel sprout formation derives from 
studies of developing blood vessels, and this is also true of tip 
cell behavior (for review see Suchting et al., 2007). Thus, 
modulation of lymphatic vessel morphogenesis and sprouting 
in particular is poorly understood, and the generalizability of 
this process to other systems that branch is also unclear. Based 
on in vitro and in vivo analyses of developing lymphatics, it 
was postulated that VEGF-C would be a positive regulator, but 
the mechanism by which it acts was not known. We show that 
Nrp2 plays the central role in modulating lymphatic tip cell 
activity to drive this behavior. Interestingly, inhibition of Nrp2 
does not affect the number of sprout initiation events. Instead, 
it increases the frequency at which these sprouts stall/retract, 
suggesting that that Nrp signaling is required to fully allow 
sprout  extension  to  manifest.  The  biochemical  basis  for   
this remains unclear and may involve the modulation of cyto-
skeletal elements by Rho family GTPases, although not ob-
served in the two-dimentional cultured LECs evaluated in 
this study. Additionally, whether this is also the case in other 
vessels and other branching systems, more broadly, is yet to 
be determined.
From a therapeutic perspective, modulation of tip cell 
biology and sprouting has several distinct advantages. It al-
lows the targeting of newly growing vessels, although allow-
ing mature quiescent vessels to remain unaffected. This is in 
contrast to modulation of growth factors that may be potential 
survival factors: modulation of these would result in targeting 
of normal quiescent vessels as well, with the possibility of un-
desirable toxicity.
In summary, our work provides novel insight into the 
central role that Nrp2, an axon guidance receptor, plays in 
lymphatic vessel development. We show for the first time that 
the cellular basis for the defect in lymphangiogenesis is a se-
lective inhibition of sprout formation, modulating lymphatic 
endothelial tip cell extension and preventing tip cell stalling 
and retraction. We also show that Nrp2 interacts genetically 
with VEGFR3, confirming previous theories and providing the 
mechanistic basis for how these two receptors act in concert to 
drive lymphatic sprouting.
domain  interacts  with  neuropilin-interacting  protein  (also 
known as synectin), a PDZ domain–containing protein that 
has been implicated in cell adhesion (Cai and Reed, 1999). 
Synectin-deficient  mice  show  defects  in  arterial  branching 
(Chittenden et al., 2006) and lymphatic vessel sprouting, which 
is similar to the ones described in this study (M. Simons, personal 
communication), suggesting that Nrp2–synectin interaction 
in  growing  lymphatic  vessel  tips  could  mediate  sprouting 
downstream of VEGFR3. Additionally, neuropilins are known 
to interact with many membrane-associated proteins that have 
been implicated in cellular migratory and cell extension be-
haviors, including integrins and plexins (Cheng et al., 2001; 
Bagri et al., 2003; Fukasawa et al., 2007; Pan et al., 2008; 
Serini et al., 2008; Uniewicz and Fernig, 2008; Valdembri et al., 
2009). As anti-Nrp2
B is known to inhibit Nrp2 interaction with 
the VEGFR signaling complex (Caunt et al., 2008), inhibition 
of Nrp2 in this scenario could result in selective modulation of 
tip cell extension.
Nrp2 interacts with VEGFR3 to promote 
lymphatic sprouting
Lymphatic development is unaltered in nrp2
+/vegfr2
+/ trans-
heterozygous mutant mice. In contrast, although both single-
heterozygous mutant mice have normal lymphatic development, 
the nrp2
+/vegfr3
+/ trans-heterozygous mutants have a dra-
matic lymphangiogenesis defect, phenocopying in vivo phar-
macologic inhibition with anti-Nrp2 antibodies and the nrp2-null 
mutant phenotype. This indicates that nrp2 genetically interacts 
with VEGFR3 but not VEGFR2. Thus, although Nrp2 can inter-
act with both VEGFRs in vitro (Favier et al., 2006) and both   
VEGFRs  are  present  on  lymphatic  endothelial  cells  during   
development in vivo, the primary VEGFR that Nrp2 interacts 
with to modulate lymphatic sprouting is VEGFR3. Although 
Nrp2 can clearly augment VEGF-C–mediated activation of both 
VEGFR2 and VEGFR3 in vitro in cellular assays (Caunt et al., 
2008), VEGFR2 appears to play a more limited role in develop-
ing lymphatics in vivo. In addition, lymphatic vessels in vivo 
bind VEGF-C strongly and VEGF-A more weakly (Fig. S5; 
Lymboussaki et al., 1999). These results indicate that despite 
VEGFR2 expression, binding of VEGF-A to LECs is ineffi-
cient, whereas VEGF-C readily binds lymphatic vessels. Dif-
ferential binding of VEGF-A and -C to endothelial cells might 
be regulated by the presence of additional coreceptors, such as 
Nrp1 and Nrp2 on microvessels and lymphatic vessels, respec-
tively. Whether VEGFR3  is  specifically  assigned  to  tip  cell   
extension is presently unclear, but recent studies have specifi-
cally implicated VEGFR3 in tip cell–associated biology even   
in  blood  vascular  endothelial  cells  (Padera  and  Jain,  2008;   
Tammela et al., 2008). Interestingly, the role of Nrp2 was not 
addressed in those studies. It is also noteworthy that anti-Nrp2
B 
specifically inhibits Nrp2’s role as a VEGF-C coreceptor while 
preserving Nrp2’s role as a semaphorin coreceptor (Caunt et al., 
2008). It also does not affect the binding of other ligands that 
have been described to interact with Nrp2, including FGFs and 
hepatocyte growth factor (Caunt et al., 2008). However, the key 
lymphatic phenotype of the nrp2-null mice and nrp2
+/vegfr3
+/ 
trans-heterozygous mice is phenocopied by treatment with the JCB • VOLUME 188 • NUMBER 1 • 2010   128
diluted to 600 pM in TBS containing 10% calf serum for 1 h at room tem-
perature. Sections were rinsed with TBS and fixed with 60% acetone, 3% 
PFA, and 20 mM Hepes, pH 7.0, for 5 min and washed with TBS. Endoge-
nous AP activity was heat inactivated by incubating the sections at 65°C 
for 3 h, and sections were processed for AP in 100 mM Tris, pH 9.5, 100 mM   
NaCl, 50 mM MgCl2, 0.1% Tween 20, 0.33 mg/ml nitroblue tetrazolium, 
and  0.05  mg/ml  BCIP  (5-bromo-4-chloro-3-indolyl-phosphate)  overnight   
at room temperature.
In vitro assays
For  the  in  vitro  sprouting  assay,  dextran-coated  microcarrier  beads   
(Cytodex 3; GE Healthcare) were incubated with LECs (400 cells/bead) in 
EGM-2MV (Lonza), which contains 200 ng/ml VEGF-C, overnight at 37°C. 
To induce clotting, 0.5 ml cell-coated beads in PBS with 2.5 µg/ml fibrinogen 
(200 beads/ml) was added into one well of a 24-well tissue culture plate 
containing 0.625 U thrombin and incubated for 5 min at room temperature 
and for 20 min at 37°C. The clot was equilibrated in EMG-2MV for 30 min 
at 37°C. The medium was replaced with EGM-2–containing skin fibroblast 
cells (Detroit 551; 20,000 cells/ml). Antibodies were added to each well, 
and the assay was monitored for 14 d with a change in medium every 2–3 
d. Images of the beads were captured by an inverted microscope, and   
the number of sprouts per bead was counted for 10 beads per condition. 
The length of the sprouts was determined in ImageJ (National Institutes   
of Health).
Time-lapse  image  series  were  acquired  with  a  live  cell  imaging   
system (Axio Observer; Carl Zeiss, Inc.) controlled by SlideBook (version 
4.2.012RC11; Intelligent Imaging Innovations, Inc.). Four beads per well 
were imaged at 20× magnification (0.62 × 0.62 µm/pixel). The xy posi-
tion of each bead was manually defined and stored, and a z stack (20 
slices with 5-µm step size) was acquired at 20-min intervals for 24 h. Sprout 
dynamics were quantified manually from the resulting 4D time series for a 
minimum of three wells per condition.
For analysis of Rho family GTPase, LECs were grown to conflu-
ence and serum starved overnight. They were then incubated in serum-
free media containing 0.1% BSA (unstimulated) or 200 ng/ml VEGF-C 
(stimulated) in the presence or absence of 40 µg/ml anti-Nrp2
B. After 
10 min of stimulation, cells were evaluated for activated Rho, Rac, or 
Cdc42  using  a  commercial  kit  (Cell  Biolabs).  VEGFR2  and  VEGFR3   
activation levels were assessed as follows: confluent human umbilical 
vein endothelial cells were stimulated for 10 min with 200 ng/ml VEGF-
C in the presence or absence of control (anti-ragweed) or anti-Nrp2
B 
antibodies. The cells were lysed and assayed, as many mediators know 
to play a role in VEGFR signaling. VEGFR2 activation was evaluated   
using  total  VEGFR2  and  phospho-VEGFR2  ELISA  assays  (DuoSet  IC 
ELISA  kit;  R&D  Systems).  VEGFR3  activation  was  evaluated  using  a   
kinase receptor activation assay with a VEGFR3-293 cell line. In brief, 
stable 293 cell lines expressing full-length Flag-tagged human VEGFR3 
were assayed for receptor phosphorylation after stimulation. 5 × 10
4 
cells were starved overnight (DME with 0.1% BSA) and stimulated with 
40 ng/ml VEGF-A (Genentech) or 200 ng/ml VEGF-C (Genentech) for 
10 min. Cells were lysed in PBS containing 1% Triton X-100 and sodium 
orthovanadate. ELISA plates were coated with capture Flag antibody 
(Sigma-Aldrich). The plates were coated overnight (PBS + 1 µg/ml anti-
body) and blocked (PBS + 0.5% BSA) for 1 h. After three washes (PBS + 
0.05% Tween 20), lysates were added for 2 h and washed three times 
followed by the addition of phospho-detection antibody 4G10 (Millipore) 
for 2 h. Detection was performed with HRP antibody (GE Healthcare) and 
tetramethylbenzidine substrate.
FACS
LECs were harvested with enzyme-free cell dissociation buffer (Invitrogen) 
and incubated with phycoerythrin-conjugated anti-VEGFR1, anti-VEGFR2, 
and anti-VEGFR3 (BD) for 2 h at 4°C at 1:100 in FACS buffer (PBS, 2% 
FBS, 2 mM EDTA, and 0.1% sodium azide) containing 5% normal mouse 
serum,  2%  normal  rat  serum,  and  10  µg/ml  human  IgG.  Cells  were 
washed with FACS buffer, and data were analyzed with the FACSCalibur 
system (BD).
Quantification of LEC replication
After  phospho–histone  H3  and  LYVE-1  double  staining,  samples  were 
mounted, and three to five fields per animal were imaged on a 20× con-
focal microscope (SP5; Leica). Only phospho–histone H3-positive cells within 
lymphatic vessels were counted. Images were processed using Photoshop 
(Adobe) and ImageJ to quantify vessel surface area and normalize repli-
cation index.
Materials and methods
Mice
For pharmacologic inhibitory experiments, neonatal CD1 mice were   
injected intraperitoneally with monoclonal antibodies at 40 mg/kg. Pharma-
cokinetic analysis and dose-ranging in vivo experiments (Fig. S1) showed 
that maximal efficacy was noted at 20 mg/kg with no additional inhibition 
of lymphatic sprouting at higher doses to 100 mg/kg. Thus, anti-Nrp2
B 
was dosed at 40 mg/kg to ensure complete saturation and inhibition of 
Nrp2. The injections were performed on P1, 3, and 5 unless otherwise 
noted. For analysis of effects on mature lymphatics, 6–8-wk-old mice were 
treated at 100 mg/ml twice a week for 25 wk. Mice were sacrificed, and 
the skin, pancreata, and intestines were collected and stained for LYVE-1.
C57/BL6  nrp2vegfr3  or  nrp2vegfr2  double-heterozygous  mice 
were generated by interbreeding nrp2
+/ mice (Giger et al., 2000) with 
vegfr3
+/lacZ (Dumont et al., 1998) or vegfr2
+/egfp mice. For vegfr2
+/egfp 
mice, a targeting construct was prepared to allow insertion of an EGFP 
reporter followed by poly(A) signal and a loxP-flanked neomycin selection 
cassette into the initiation codon within exon 1 of the flk1 locus. We   
retained all sequence elements of the locus to avoid deletion of potential 
regulatory elements. Linearized targeting vector was electroporated into 
mouse embryonic stem (ES) cell line E14Tg2a, and the targeted clones 
were selected by Southern blotting. The floxed selection cassette in the 
vector was excised by Cre-mediated recombination in targeted ES cells 
by transient transfection with a Cre-expressing plasmid. Chimeric mice 
were produced after injection of correctly targeted ES cells into blasto-
cysts and were back crossed to the C57/BL6 background for at least   
nine  generations.  The  Flk1-GFP  embryos  showed  a  typical  vascular   
pattern of expression.
Colonies of nrp2
+/, vegfr2
+/egfp, and vegfr3
+/lacZ mice were main-
tained by breeding heterozygous males with wild-type C57/BL6 females 
(Charles River). Genotyping was performed using PCR beads (Ready- 
  To-Go; GE Healthcare).The following primers were used for genotyping 
nrp2: forward primer 1, 5-CGCATTGCATCAGCCATGAT-3; forward 
primer 2, 5-TCAGGACACGAAGTGAGAAG-3; and reverse primer,   
5-GGGAGATGTGTTCTGCTTCA-3. The following primers were used 
for genotyping vegfr3: forward primer 1, 5-GCGGTCTGAAAGGAAGA-
CAG-3; forward primer 2, 5-ACTGGCAGATGCACGGTTAC-3; reverse 
primer 1, 5-ACACCAAGCCAAGCTCAAGT-3; and reverse primer 2, 
5-GTT GCACCACAGATGAAACG-3. vegfr2
+/egfp mice were identified 
by fluorescence.
Immunohistochemistry
For whole-mount staining, tissues were fixed in 4% PFA and blocked over-
night in blocking buffer (PBS, 5% goat serum, 0.3% Triton X-100, and   
0.2% BSA). Tissues were incubated overnight at 4°C with primary antibodies 
in blocking buffer (biotinylated or unconjugated anti–mouse VEGFR3 [R&D 
Systems],  anti–mouse  LYVE-1  [R&D  Systems  or  Angiobio],  anti–mouse 
podoplanin [R&D Systems], phospho–histone H3 [Abcam], anti–PECAM-1 
[BD], and VE-cadherin [Cell Signaling Technology]). Tissues were washed 
in PBS and 0.3% Triton X-100 and incubated overnight with fluorescent   
streptavidin (Cy2 or Cy3; GE Healthcare) or species-specific fluorescent 
secondary antibodies (Alexa Fluor 488 or 555; 1:200; Invitrogen). For tail 
whole-mount  preparation,  tails  were  dissected,  a  longitudinal  cut  was 
made down the dorsal length of the tail, and the tail bone was removed. 
Tails were incubated with 20 mM EDTA and PBS for 4 h at 37°C to remove 
the epidermis and were fixed with 4% PFA for 3 h at room temperature. For 
immunocytochemistry on LECs, cells were grown to confluence and serum 
starved overnight. They were incubated in serum-free media containing 
0.1% BSA (unstimulated) or 200 ng/ml VEGF-C (stimulated) in the pres-
ence or absence of 40 mg/ml anti-Nrp2
B. Cells were stained with anti-
bodies to LYVE-1, VE-cadherin and tubulin (Cell Signaling Technology), or 
Alexa Fluor 488 phalloidin (Invitrogen).
Mouse VEGF-C–AP and VEGF-A–AP constructs (provided by C. Ruiz 
de Almodovar, Vesalius Research Center, Leuven, Belgium) were obtained 
by cloning cDNA encoding mouse VEGF-A and VEGF-C into pAPtag-5 
vector (GenHunter Corporation). To produce AP-tagged proteins, HEK293T 
cells were transfected using Lipofectamine plus (Invitrogen). Supernatant 
was collected after 48 h, and AP concentration was measured using   
p-nitrophenyl phosphate tablets (Sigma-Aldrich). VEGF-A– and VEGF-C–
AP-binding experiments were performed on cryostat sections of tails from 
p6 mice or diaphragms as described previously (Feiner et al., 1997). In 
brief, fresh frozen tissue sections were postfixed in precooled methanol at 
20°C for 10 min and washed with TBS, blocked with TBS containing 
10% calf serum for 15 min, and incubated with AP ligand fusion protein 129 Nrp-2 mediates lymphatic sprouting • Xu et al.
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Quantification of lymphatic vessel branch points
The dorsal skin surrounding the forelimbs from P0 pups was stained for 
VEGFR3, LYVE-1, or X-gal (Invitrogen), imaged on a 4× stereomicroscope, 
and branch points were counted manually. Only skin samples from the dor-
sal part of the pup surrounding the forelimb were quantified to ensure   
reproducibility between pups.
Quantitative PCR
Hearts  were  isolated  from  P5  wild-type,  nrp-2
+/,  vegfr2
+/egfp,  and   
nrp-2
+/vegfr3
+/lacz mice, and total mRNA was extracted using a total RNA 
extraction kit (MiniKit; QIAGEN). Four independent samples were ana-
lyzed for each genotype. RNA was reverse transcribed using Superscript 
III (Invitrogen) and random primers according to the manufacturer’s instruc-
tions.  Quantitative  PCR  was  performed  with  a  real-time  PCR  detection   
system  (iCycler;  Bio-Rad  Laboratories)  using  SYBR  green  PCR  master   
mix (Bio-Rad Laboratories) and standard thermocycler conditions. PCRs 
were performed in duplicate in a total volume of 25 µl using 1 µl cDNA. 
Each sample was analyzed for -actin to normalize for RNA input amounts 
and to perform relative quantifications. Levels of each transcript in one 
wild-type animal were set at 1. The following primers were used: mouse 
flk1,  5-GCCCTGCTGTGGTCTCACTAC-3  and  5-GCCCATTCGATC-
CAGTTTCA-3; mouse Pecam1, 5-CAAGCAAAGCAGTGAAGCTG-3 
and 5-TCTAACTTCGGCTTGGGAAA-3; and mouse -actin, 5-TGTTAC-
CAACTGGGACGACA-3  and  5-GGGGTGTTGAAGGTCTCAAA-3.  Mouse 
flt4, Lyve1, podoplanin, prox1, and nrp2 genes were detected using pre-
designed primer pairs (QuantiTect primer assays; QIAGEN). Melting curve 
analysis showed a single, sharp peak with the expected temperature melt-
ing for all samples.
Image acquisition and analysis
For Figs. 1 (N and R), 5, 7, 8 (C–E), S2, and S3, tissues stained with Alexa 
Fluor 555 and 488 (Invitrogen) were used mounted in type F immersion 
liquid  (Leica),  and  images  were  captured  with  a  confocal  microscope 
(Sp5; Leica) at room temperature with acquisition software (LAS AF; Leica) 
and a 10× NA 0.3 Plan Fluotar lens (HC; Leica), a 20× NA 0.7 Plan Apo 
lens (HCX CS; Leica), and a 40× NA 1.4 Plan Apo lens (HCX CS; Leica).
For Figs. 1 (all panels except panels N, O, R, and S), 2 (A–D, G, 
and H), 3, and S1, tissues stained with Alexa Fluor 555 and 488 were 
used mounted in Fluoromount G (EMS Sciences), and images were cap-
tured with an upright microscope (Axioplan2; Carl Zeiss, Inc.) at room 
temperature with a charge-coupled device (HQ2; Photometrics) camera 
  using SlideBook (version 5.0) software and 5×, 10×, and 20× objectives 
with NA 0.16, 0.45, and 0.75, respectively (Carl Zeiss, Inc.).
For Figs. 2 (M–P), 6 (A–D), 8 (A and B), and S4 (A–K), tissues 
stained with Alexa Fluor 555 and 488 were wet mounted in PBS, and im-
ages were captured with a microscope (FX MZ FL111 DFC 340; Leica) at 
room temperature on a compact flash camera (CoolSNAP; Photometrics) 
with acquisition software (Fire Cam; Leica) and a 10× HC Plan Fluotar NA 
0.3 lens, a 20× HCX Plan Apo CS NA 0.7 lens, and a 40× NA 1.4 HCX 
Plan Apo CS lens.
For Figs. 6 (E and F), S4 (L–O), and S5, tissues were chromogeni-
cally stained or stained with Alexa Fluor 555 and 488, were mounted in 
DakoCytomation  mounting  media  (Dako),  and  images  were  captured 
with a microscope (BX50; Olympus) at room temperature on a compact 
flash camera (CoolSNAP; Photometrics) with acquisition software (Iplab 
3.2.4; Scanalytics, Inc.) and a 4× NA 0.16 UPlan Apo lens, a 10× NA 
0.3 UPlan FL lens, and a 20× NA 0.5 UPlan FL lens. Imaris software (ver-
sion x64; Bitplan) was used to generate 3D surface renderings of z-stack 
40× confocal images depicted in Fig. 1 (N and R) to generate the images 
in Fig. 1 (O and S), respectively.
Online supplemental material
Fig. S1 shows concentration dependence of anti-Nrp2
B and analysis of 
mature lymphatics in control and anti-Nrp2
B–treated mice. Fig. S2 shows 
expression of Nrp2, VEGFR2, and VEGFR3 in developing lymphatics in vitro 
and in vivo. Fig. S3 shows effects of Nrp2 inhibition on cytoskeletal behavior, 
VEGFR activation, and cellular junctions in vitro and in vivo. Fig. S4 shows 
analysis of lymphatic structure and function in nrp2
/ and nrp2
+/vegfr3
+/ 
mice. Fig. S5 shows that VEGF-C–AP selectively binds to lymphatic vessels 
and sprouts. Online supplemental material is available at http://www.jcb 
.org/cgi/content/full/jcb.200903137/DC1.
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